Artoss Announces NanoBone® QD Bone Graft


Press Release October 23, 2017

Artoss, Inc. is pleased to announce NanoBone QD Bone Graft.

Paul Byerley, Managing Director of Artoss, Inc., the exclusive North American distributors for NanoBone in orthopaedic surgery, said, “To extend the usability of NanoBone, we put the perfect handling of NanoBone SBX Putty in an applicator designed for QD – quick delivery. This easy-to-use device facilitates rapid implantation of our advanced bone graft in a controlled and precise manner. Artoss developed NanoBone QD to provide these benefits in a cost-effective delivery system.”

Walter Gerike, Managing Director of Artoss GmbH said, “Nanotechnology is the key technology for the 21st century and Artoss is harnessing this potential for orthopaedic surgery. With the launch of NanoBone SBX Putty in 2016, we created a product that combines Applied NanoBiology™ for bone repair with perfect handling for the surgeon. NanoBone QD takes the product one step further by making it easier for the surgeon to implant.” NanoBone synthetic bone graft products have been used in Europe and the US for more than ten years in approaching 400,000 clinical cases across all indications and has been available in the United States since 2015.

Artoss, Inc. is launching NanoBone QD at the North American Spine Society Meeting this week. Visit them at Booth 1562 to learn more.
NanoBone QD applicator
For further information, please contact:

Artoss, Inc.15900 155th St. NE
Foley, MN 56329
320-355-4321
info@artossinc.com

info@artossinc.com

Artoss, Inc. Announces Hiring of Ryan O’Neill as Director of Sales, Eastern Region


Press Release October 9, 2017

Artoss, Inc. is pleased to announce the hiring of Ryan O’Neill as Director of Sales, Eastern Region. In this role, Ryan will be responsible for introducing NanoBone® Bone Graft in the eastern half of the United States and for identifying, training, and managing independent distributors in that region.

Paul Byerley, Managing Director of Artoss, Inc., the exclusive North American distributors for NanoBone in orthopaedic surgery, said, “Ryan has built a very successful career by introducing new biologic technologies pioneered by small innovative companies. He was a great asset when we worked together at ApaTech and I’m sure he’ll contribute to the continued growth of NanoBone sales in the US.”

“I’m excited to be educating orthopaedic and neurosurgeons about the concepts of Applied NanoBiology™ and the importance of nanostructured biomaterials to their practices”, said Ryan. “It’s good to be working with Paul and Jim again, bringing the next generation of advance bone grafting technology to patients.”

NanoBone Bone Graft products have been used in Europe and the US for more than ten years in approaching 400,000 clinical cases across all indications. They have been available in the United States through Artoss, Inc. since 2015.

For further information, please contact:

Artoss, Inc.
15900 155th St. NE
Foley, MN 56329
320-355-4321
info@artossinc.com

info@artossinc.com

Artoss, Inc. Announces DAPA Agreement for NanoBone® Bone Graft Products


Press Release September 15, 2017

Artoss, Inc. is pleased to announce that the full line of NanoBone Bone Graft products are now available through a Defense Acquisition Purchasing Agreement (DAPA) with the Prime Vendor, Owens & Minor. This will allow surgeons in any US Department of Defense healthcare facility to purchase NanoBone Bone Graft for use in surgery.

Paul Byerley, Managing Director of Artoss, Inc., the exclusive North American distributors for NanoBone in orthopaedic surgery, said, “Nanotechnology is the key technology for the 21st century and NanoBone Bone Graft brings Applied NanoBiology™ to bone repair. We are proud to provide NanoBone to military surgeons that are providing the highest quality of care to our men and women in uniform.”

NanoBone Bone Graft products have been used in Europe and the US for more than ten years in approaching 400,000 clinical cases across all indications. They have been available in the United States through Artoss, Inc. since 2015.

For further information, please contact:

Artoss, Inc.
15900 155th St. NE
Foley, MN 56329
320-355-4321
info@artossinc.com

Artoss Announces FDA Clearance to Market of NanoBone SBX Putty


Press Release November 8, 2016

Artoss, Inc. is pleased to announce that, on October 26, 2016, Artoss GmbH received notice from the U.S. Food & Drug Administration that NanoBone® SBX Putty has been cleared to market as 510(k) K161351.

Walter Gerike, Managing Director of Artoss GmbH said, “Nanotechnology is the key technology for the 21st century and Artoss is harnessing this potential for orthopaedic surgery. In NanoBone SBX Putty, we have a product that combines Applied NanoBiology™ for bone repair with perfect handling for the surgeon.” NanoBone synthetic bone graft products have been used in Europe for ten years in approaching 400,000 clinical cases across all indications.

James J. Cassidy, Ph.D., Managing Director of Artoss, Inc., the exclusive North American distributors for NanoBone in orthopaedic surgery, stated, “NanoBone technology has been in great demand by U.S. surgeons since we launched NanoBone Granules in 2015. NanoBone SBX Putty offers the same clinical performance in an easier to use presentation. We look forward to introducing this product in a variety of sizes to the U.S. market in the coming weeks.”

Contact:

Artoss, Inc.
15900 155th St. NE
Foley, MN 56329
320-355-4321
info@artossinc.com